<DOC>
	<DOCNO>NCT01211756</DOCNO>
	<brief_summary>The objective study compare efficacy intranasal oxytocin versus intranasal placebo improve depression symptom patient Major Depressive Disorder ( MDD ) Dysthymia Disorder .</brief_summary>
	<brief_title>Oxytocin Add-on Stable Depressed Patients</brief_title>
	<detailed_description>Depression patient treat even best currently available antidepressant drug continue experience significant symptom . There strong need well treatment include treatment safely give adjunctively concurrent antidepressant order improve overall efficacy treatment . Oxytocin neurohypophyseal peptide best know role neurohormone involve parturition lactation . In addition well establish peripheral effect , compel body converge evidence indicate oxytocin play critical role regulation number diverse centrally-mediated behavioral cognitive process highly relevant mood regulation mood disorder , include social attachment ( Argiolas Gessa 1990 ; McCarthy Aaltemus 1997 ) . Each subject enrol 8 week treatment period screen phase . Study procedure involve weekly clinic visit outpatient . Twenty patient randomly assign either 40 IU oxytocin twice daily vehicle placebo . After 4 week , treatment cross subject receive oxytocin receive placebo vice versa . The study ratio 1:1 . Dose oxytocin base upon previous study human show improvement psychiatric population relate change behavior brain function ( Kosfeld et al , 2005 ; Kirsch 2005 ; Heinrich M 2003 ) . The total study duration individual subject approximately 9 week , include 31-day screening period , baseline ( randomization ) visit , four week treatment period , 1 week washout , baseline 2 visit , four week cross treatment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Dysthymic Disorder</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1 . Adult men woman , 18 year age old . 2 . Meet DSMIV criterion Major Depressive Disorder Dysthymia Disorder 3 . Women childbearing potential must test negative pregnancy time enrollment base urine pregnancy test agree use reliable method birth control study . 4 . Must therapeutic dose 1 2 antidepressant major dose change least 4 week randomization . 5 . MADRS score &gt; 17 randomization 6 . Have Clinical Global ImpressionsSeverity ( CGIS ) scale score least 4 ( moderately ill ) baseline . 7 . Must able communicate effectively investigator study coordinator ability provide inform consent . 8 . Must able use nasal spray 9 . Must demonstrate acceptable degree compliance medication procedure opinion investigator . ( If patient he/she consider acute portion study . ) Permitted : Subjects 2 sleep medication ( diphenhydramine , zolpidem , zaleplon , diazepam ) , reasonable dose , judge investigator , permit study . Minor adjustment sleep medication acceptable . Patients ask notify study doctor change sleep aid . Subjects exclude study meet follow criterion : 1 . Are pregnant breastfeeding ( negative pregnancy test screening ) 2 . A urine drug screen perform screen must show evidence recent use drug abuse 3 . Any active medical condition opinion investigator interfere objective study 4 . Are unsuitable way participate study , opinion investigator . 5 . Another current DSMIV diagnosis Major Depressive Disorder Dysthymia Disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>